Cargando…
The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials
BACKGROUND: Ascites is the most common complication of cirrhosis. It may lead to the consequence of poor prognosis and the deterioration of quality of life. Asopressin V2 receptor antagonists is a kind of vaptans, and it has been proved to be effective in hyponatremia patients. We conducted a meta-a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460759/ https://www.ncbi.nlm.nih.gov/pubmed/26054761 http://dx.doi.org/10.1186/s12876-015-0297-z |
_version_ | 1782375430973554688 |
---|---|
author | Yan, Long Xie, Feng Lu, Jiongjiong Ni, Qingqiang Shi, Changying Tang, Caixi Yang, Jiamei |
author_facet | Yan, Long Xie, Feng Lu, Jiongjiong Ni, Qingqiang Shi, Changying Tang, Caixi Yang, Jiamei |
author_sort | Yan, Long |
collection | PubMed |
description | BACKGROUND: Ascites is the most common complication of cirrhosis. It may lead to the consequence of poor prognosis and the deterioration of quality of life. Asopressin V2 receptor antagonists is a kind of vaptans, and it has been proved to be effective in hyponatremia patients. We conducted a meta-analysis about treatment of vaptans in cirrhosis patients with ascites. METHODS: Following our selection criteria, we collected a total of 14 studies containing 16 randomized controlled trials (2620 patients) from a series of database about the treatment with vaptans for cirrhosis with ascites patients. The included studies compared the treatment effect of lixivaptan (VPA 985), or RMJ-351647, or satavaptan, or tolvaptan with placebo. RESULTS: The included vaptans (asopressin V2 receptor antagonists) showed significant effect of increasing the serum sodium concentration for cirrhosis patients (WMD = 2.11 mmol/L, p < 0.00001). Patients also could acquire significant improvement of ascites, as this kind of aquaretics can significantly reduce ascites patients’ weight (WMD = −1.53, p < 0.00001), abdominal girth (WMD = −2.04, p < 0.00001), and the ratio of worsening ascites (RR = 0.51, p = 0.001). Though the drug did not produce more total adverse events (RR = 1.04, p = 0.09) and the total serious events (RR = 1.04, p = 0.42), the emergence of excessive correction of serum sodium concentrations (>145 mmol/L) was more frequently noted in patients under the employment of vaptans (RR = 2.14, 95 % CI [1.45, 3.16], p = 0.0001). Whether with the administration of vaptans for short-term or long-term, no survival benefit was detected from the selected studies. CONCLUSIONS: Asopressin V2 receptor antagonists could play an effective and safe role in symptomatic treatment for cirrhosis patients with ascites, especially for refractory ascites patients who presented insufficient response to conventional diuretics. |
format | Online Article Text |
id | pubmed-4460759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44607592015-06-10 The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials Yan, Long Xie, Feng Lu, Jiongjiong Ni, Qingqiang Shi, Changying Tang, Caixi Yang, Jiamei BMC Gastroenterol Research Article BACKGROUND: Ascites is the most common complication of cirrhosis. It may lead to the consequence of poor prognosis and the deterioration of quality of life. Asopressin V2 receptor antagonists is a kind of vaptans, and it has been proved to be effective in hyponatremia patients. We conducted a meta-analysis about treatment of vaptans in cirrhosis patients with ascites. METHODS: Following our selection criteria, we collected a total of 14 studies containing 16 randomized controlled trials (2620 patients) from a series of database about the treatment with vaptans for cirrhosis with ascites patients. The included studies compared the treatment effect of lixivaptan (VPA 985), or RMJ-351647, or satavaptan, or tolvaptan with placebo. RESULTS: The included vaptans (asopressin V2 receptor antagonists) showed significant effect of increasing the serum sodium concentration for cirrhosis patients (WMD = 2.11 mmol/L, p < 0.00001). Patients also could acquire significant improvement of ascites, as this kind of aquaretics can significantly reduce ascites patients’ weight (WMD = −1.53, p < 0.00001), abdominal girth (WMD = −2.04, p < 0.00001), and the ratio of worsening ascites (RR = 0.51, p = 0.001). Though the drug did not produce more total adverse events (RR = 1.04, p = 0.09) and the total serious events (RR = 1.04, p = 0.42), the emergence of excessive correction of serum sodium concentrations (>145 mmol/L) was more frequently noted in patients under the employment of vaptans (RR = 2.14, 95 % CI [1.45, 3.16], p = 0.0001). Whether with the administration of vaptans for short-term or long-term, no survival benefit was detected from the selected studies. CONCLUSIONS: Asopressin V2 receptor antagonists could play an effective and safe role in symptomatic treatment for cirrhosis patients with ascites, especially for refractory ascites patients who presented insufficient response to conventional diuretics. BioMed Central 2015-06-09 /pmc/articles/PMC4460759/ /pubmed/26054761 http://dx.doi.org/10.1186/s12876-015-0297-z Text en © Yan et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Yan, Long Xie, Feng Lu, Jiongjiong Ni, Qingqiang Shi, Changying Tang, Caixi Yang, Jiamei The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials |
title | The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials |
title_full | The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials |
title_fullStr | The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials |
title_full_unstemmed | The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials |
title_short | The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials |
title_sort | treatment of vasopressin v2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460759/ https://www.ncbi.nlm.nih.gov/pubmed/26054761 http://dx.doi.org/10.1186/s12876-015-0297-z |
work_keys_str_mv | AT yanlong thetreatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT xiefeng thetreatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT lujiongjiong thetreatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT niqingqiang thetreatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT shichangying thetreatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT tangcaixi thetreatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT yangjiamei thetreatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT yanlong treatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT xiefeng treatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT lujiongjiong treatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT niqingqiang treatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT shichangying treatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT tangcaixi treatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials AT yangjiamei treatmentofvasopressinv2receptorantagonistsincirrhosispatientswithascitesametaanalysisofrandomizedcontrolledtrials |